Analysed MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) News Sources
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
23-03-2026
yahoo.com
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
03-02-2026
yahoo.com
Starfish Space Completes Autonomous Rendezvous and Proximity Mission in LEO with Impulse Space
15-12-2025
yahoo.com
Specialist Direct's ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes
30-10-2025
yahoo.com
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
24-10-2025
yahoo.com
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
16-10-2025
yahoo.com
What is the current price of MIRA PHARMACEUTICALS INC (MIRA:NASDAQ)?
The current price of MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) is $0.9965.
MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) absolute price change since previous trading day?
The absolute price change of MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) since the previous trading day is $-0.0235.
MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) percentage price change since previous trading day?
The percentage price change of MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) since the previous trading day is -2.3039%.
What is the most recent average sentiment score for MIRA PHARMACEUTICALS INC (MIRA:NASDAQ)?
The most recent average sentiment score for MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for MIRA PHARMACEUTICALS INC (MIRA:NASDAQ)?
The most recent sentiment for MIRA PHARMACEUTICALS INC (MIRA:NASDAQ) is .
SEC-8K** Filing Available For MIRA PHARMACEUTICALS INC (MIRA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.